Sanofi (EPA:SAN)
82.32
-0.40 (-0.48%)
At close: Jan 2, 2026
Sanofi Revenue
Sanofi had revenue of 13.17B EUR in the quarter ending September 30, 2025, with 1.49% growth. This brings the company's revenue in the last twelve months to 45.93B, up 7.29% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 6.41% growth.
Revenue (ttm)
45.93B
Revenue Growth
+7.29%
P/S Ratio
2.19
Revenue / Employee
554.20K
Employees
82,878
Market Cap
100.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Sanofi News
- 1 day ago - Witnessing An Insider Decision, George L Sing Exercises Options Valued At $2.32M At Regeneron Pharmaceuticals - Benzinga
- 2 days ago - Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump - Reuters
- 2 days ago - Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX - PRNewsWire
- 3 days ago - Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan - Benzinga
- 3 days ago - Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX - Business Wire
- 8 days ago - Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk - Seeking Alpha
- 8 days ago - Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why - Benzinga
- 9 days ago - What Sanofi Is Getting Through The Acquisition Of Dynavax - Seeking Alpha